3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
10
Condylomata Acuminata
10
Papillomavirus Infections
5
Vulvar Neoplasms
3
Vaginal Neoplasms
3
Uterine Cervical Dysplasia
1
Penile Neoplasms
1
Neoplasms
1
Cancer Survivor
1
Anus Neoplasms
1
Interventions
Colposcopy
15
Imiquimod
13
Conization
11
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
7
Cryotherapy
7
Papillomavirus Vaccines
6
Biopsy
6
Acetic Acid
6
human papillomavirus vaccine, L1 type 16, 18
5
Vaginal Smears
5
Watchful Waiting
4
Human Papillomavirus DNA Tests
4
Vaccines
3
Blood Specimen Collection
3
VGX-3100
2
Transurethral Resection of Prostate
2
Spectrometry, Fluorescence
2
Restraint, Physical
2
Proflavine
2
Polymerase Chain Reaction
2
Mass Screening
2
Indomethacin
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
High-Throughput Screening Assays
2
GX-188 vaccine
2
Fluorouracil
2
Flow Cytometry
2
Cyclophosphamide
2
Curcumin
2
Celecoxib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Uterine Cervical Dysplasia
×
Vaccines, Synthetic
×
Clear all
NCT03493542
2024-12-31
V501-213
Merck Sharp & Dohme LLC
Phase 3
Completed
766 enrolled
38 charts